PREVENT and SCORE2 Prediction Tools Perform Well in Global Cohort

Why It Matters

Robust validation across heterogeneous populations gives clinicians confidence to use PREVENT and SCORE2 for personalized cardiovascular risk assessment, supporting guideline adoption and improving primary‑care decision‑making worldwide.

Key Takeaways

• PREVENT validated in 2 million new patients, total 8.4 million
• Both tools show C‑statistic ~0.70, strong discrimination overall
• Performance best in low‑ and intermediate‑risk groups, aiding primary care
• PREVENT‑ASCVD aligns closely with SCORE2, useful for European cohorts
• Adding albuminuria improves PREVENT discrimination for CVD, ASCVD, HF

Pulse Analysis

Risk prediction tools are the backbone of modern cardiovascular prevention, translating complex patient data into actionable risk scores. The PREVENT suite, introduced by the American Heart Association in 2023, expands beyond traditional pooled cohort equations by estimating 10‑ and 30‑year risks for myocardial infarction, stroke, and heart failure, starting at age 30. Its broader clinical scope—covering kidney and metabolic markers—positions it as a versatile instrument for clinicians navigating the growing burden of multimorbidity.

The latest validation effort, published in Nature Medicine, pooled data from 62 studies, including 18 randomized trials of SGLT2 inhibitors, GLP‑1 agonists, and mineralocorticoid antagonists. With more than 8 million individuals represented, the analysis confirms that both PREVENT and SCORE2 retain moderate to favorable discrimination (C‑statistics ~0.70) across continents, sexes, and age brackets. Notably, the calculators excel in low‑ and intermediate‑risk cohorts, where primary‑care providers most often decide on preventive therapies, reinforcing their utility in everyday practice.

Looking ahead, the findings encourage broader guideline endorsement and integration into electronic health records, where real‑time risk calculation can streamline treatment pathways. Adjustments such as incorporating albuminuria further sharpen PREVENT’s predictive power, especially for heart‑failure outcomes. While modest over‑estimation persists in some Asian and under‑represented groups, the overall calibration surpasses legacy models, offering a more reliable foundation for global cardiovascular risk management.